Yıl: 2020 Cilt: 35 Sayı: 1 Sayfa Aralığı: 20 - 28 Metin Dili: İngilizce DOI: 10.5606/ArchRheumatol.2020.7294 İndeks Tarihi: 10-10-2020

Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests

Öz:
Objectives: This study aims to analyze the coherence between T-SPOT tuberculosis test (T-SPOT.TB) and tuberculin skin test (TST) with differentcut-off values in screening latent tuberculosis infection (LTBI) both prior to and at the sixth month of anti-tumor necrosis factor (anti-TNF) treatment.Patients and methods: This prospective multicentric study included 57 children (34 girls, 23 boys, mean age 12.4±3.9 years; range, 6 to 18 years)diagnosed with immune-mediated inflammatory diseases (IMIDs) evaluated with TST and T-SPOT.TB for screening LTBI both prior to and at the sixthmonth of treatment with anti-TNF agents. Coherence between two tests was analyzed for TST cut-off values suggested by the local guidelines andalso for different possible cut-off values of TST.Results: Tuberculin skin test was positive (≥5 mm) in 28.1% (n=16) of patients in the screening prior to treatment and in 33.3% (n=19) at the sixthmonth of treatment. T-SPOT.TB test was positive in 8.8% (n=5) of patients both prior to and at the sixth month of treatment. Coherence between twotests was poor or fair when compared with all possible TST cut-off values both prior to and at the sixth month of anti-TNF therapy.Conclusion: Our results show poor coherence between T-SPOT.TB and TST for all possible cut-off values of TST. Thus, using both tests would bebeneficial in screening LTBI until further studies bring new evidence on the subject.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
  • 2. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-21.
  • 3. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
  • 4. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75.
  • 5. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-47.
  • 6. Hanta I, Ozbek S, Kuleci S, Seydaoglu G, Ozyilmaz E. Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNFa therapy: tuberculin skin test versus IFN-g assay. Rheumatol Int 2012;32:3599-603.
  • 7. Farhat M, Greenaway C, Pai M, Menzies D. Falsepositive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204.
  • 8. Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis 2007;20:264-71.
  • 9. Marques CD, Duarte ÂL, de Lorena VM, Souza JR, Souza WV, Gomes Yde M, et al. Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis. Rheumatol Int 2009;30:57-62.
  • 10. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-g release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55.
  • 11. Domínguez J, Ruiz-Manzano J, De Souza-Galvão M, Latorre I, Milà C, Blanco S, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008;15:168-71.
  • 12. Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007;11:1177-82.
  • 13. Camlar SA, Makay B, Appak O, Appak YC, Esen N, Günay T, et al. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1189-93.
  • 14. Kalfa M, Aksu K. Treatment with tumor necrosis factor-alpha antagonists and infections. RAED Journal 2011;3:49-56.
  • 15. Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704-12.
  • 16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
  • 17. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
  • 18. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
  • 19. Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-a reagents. Pediatr Rheumatol Online J 2014;12:45.
  • 20. Menzies D, Pai M, Comstock G. Metaanalysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54.
  • 21. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59:1-25.
  • 22. Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, et al. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 2009;36:2029-32.
  • 23. Barut K, ahin S, Adrovic A, Köker M, Kılıç Ö, Camcıo¤lu Y, et al. Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy Turk J Med Sci 2018;48:1109-14.
  • 24. Atikan BY, Cavusoglu C, Dortkardesler M, Sozeri B. Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population. Clin Rheumatol 2016;35:427-31.
  • 25. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti- TNF-a agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012;32:2675-9.
  • 26. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6.
  • 27. Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, Smith KC. Comparing the tuberculin skin test and T-SPOT. TB blood test in children. Pediatrics 2011;127:31-8.
  • 28. Abubakar I, Stagg HR, Whitworth H, Lalvani A. How should I interpret an interferon gamma release assay result for tuberculosis infection? Thorax 2013;68:298-301.
  • 29. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. Eur Respir J 2007;30:722-8.
  • 30. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017;64:e1-e33.
  • 31. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
  • 32. Anti-TNF kullanan hastalarda tüberküloz rehberi. Ankara: TC Sa¤lık Bakanlı¤ı, Türkiye Halk Sa¤lı¤ı Kurumu; 2016.
  • 33. Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018;8:e022445.
APA GİRİT s, Atabek A, Senol E, Kockar Kizilirmak T, PEKCAN S, Goktas S, OKTEM S, Kasapcopur O, cokugras H (2020). Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. , 20 - 28. 10.5606/ArchRheumatol.2020.7294
Chicago GİRİT saniye,Atabek Ayse Ayzit,Senol Ebru,Kockar Kizilirmak Tuba,PEKCAN SEVGI,Goktas Safak,OKTEM SEDAT,Kasapcopur Ozgur,cokugras Haluk Cezmi Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. (2020): 20 - 28. 10.5606/ArchRheumatol.2020.7294
MLA GİRİT saniye,Atabek Ayse Ayzit,Senol Ebru,Kockar Kizilirmak Tuba,PEKCAN SEVGI,Goktas Safak,OKTEM SEDAT,Kasapcopur Ozgur,cokugras Haluk Cezmi Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. , 2020, ss.20 - 28. 10.5606/ArchRheumatol.2020.7294
AMA GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. . 2020; 20 - 28. 10.5606/ArchRheumatol.2020.7294
Vancouver GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. . 2020; 20 - 28. 10.5606/ArchRheumatol.2020.7294
IEEE GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H "Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests." , ss.20 - 28, 2020. 10.5606/ArchRheumatol.2020.7294
ISNAD GİRİT, saniye vd. "Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests". (2020), 20-28. https://doi.org/10.5606/ArchRheumatol.2020.7294
APA GİRİT s, Atabek A, Senol E, Kockar Kizilirmak T, PEKCAN S, Goktas S, OKTEM S, Kasapcopur O, cokugras H (2020). Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives of Rheumatology, 35(1), 20 - 28. 10.5606/ArchRheumatol.2020.7294
Chicago GİRİT saniye,Atabek Ayse Ayzit,Senol Ebru,Kockar Kizilirmak Tuba,PEKCAN SEVGI,Goktas Safak,OKTEM SEDAT,Kasapcopur Ozgur,cokugras Haluk Cezmi Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives of Rheumatology 35, no.1 (2020): 20 - 28. 10.5606/ArchRheumatol.2020.7294
MLA GİRİT saniye,Atabek Ayse Ayzit,Senol Ebru,Kockar Kizilirmak Tuba,PEKCAN SEVGI,Goktas Safak,OKTEM SEDAT,Kasapcopur Ozgur,cokugras Haluk Cezmi Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives of Rheumatology, vol.35, no.1, 2020, ss.20 - 28. 10.5606/ArchRheumatol.2020.7294
AMA GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives of Rheumatology. 2020; 35(1): 20 - 28. 10.5606/ArchRheumatol.2020.7294
Vancouver GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. Archives of Rheumatology. 2020; 35(1): 20 - 28. 10.5606/ArchRheumatol.2020.7294
IEEE GİRİT s,Atabek A,Senol E,Kockar Kizilirmak T,PEKCAN S,Goktas S,OKTEM S,Kasapcopur O,cokugras H "Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests." Archives of Rheumatology, 35, ss.20 - 28, 2020. 10.5606/ArchRheumatol.2020.7294
ISNAD GİRİT, saniye vd. "Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests". Archives of Rheumatology 35/1 (2020), 20-28. https://doi.org/10.5606/ArchRheumatol.2020.7294